Monkeypox(CP00071.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Monkeypox
CP00071.US
News
View More

Gilead Sciences Reports Publication of Phase 3 Trial Results of Trodelvy and Keytruda for Breast Cancer

Gilead Sciences Reports Publication of Phase 3 Trial Results of Trodelvy and Keytruda for Breast Cancer

marketscreener·
US
IXJ
+1.47%
US
IBBQ
+2.40%
US
IHE
+1.46%
marketscreener·
US
IXJ
+1.47%
US
IBBQ
+2.40%
US
IHE
+1.46%

New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results

Gilead Sciences Inc :NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Reuters·
US
IBBQ
+2.40%
US
IBB
+2.60%
US
IHE
+1.46%
Reuters·
US
IBBQ
+2.40%
US
IBB
+2.60%
US
IHE
+1.46%

Viatris Inc. Stock Rises Wednesday, Outperforms Market

Shares of Viatris Inc. (VTRS) rose 3.08% to $13.05 on Wednesday, outperforming the market as the S&P 500 and Dow Jones also saw gains. The stock is currently 3.26% below its 52-week high of $13.49, reached on January 14th. Trading volume was 7.8 million, slightly below the 50-day average of 8.8 million.

Dow Jones·
US
IHE
+1.46%
US
VTRS
+3.08%
US
IXJ
+1.47%
Dow Jones·
US
IHE
+1.46%
US
VTRS
+3.08%
US
IXJ
+1.47%

Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC

Gilead Sciences Inc. announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial, published in The New England Journal of Medicine. The study showed that Trodelvy® combined with Keytruda® significantly improved progression-free survival in patients with PD-L1+ metastatic triple-negative breast cancer, reducing the risk of disease progression or death by 35% compared to Keytruda plus chemotherapy. Median progression-free survival was 11.2 months for the combination therapy versus 7.8 months for the control. Gilead has submitted applications to the FDA and EMA for this indication.

Reuters·
US
IHE
+1.46%
US
GILD
+4.00%
US
IBB
+2.60%
Reuters·
US
IHE
+1.46%
US
GILD
+4.00%
US
IBB
+2.60%

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Gilead Sciences Inc. (GILD) shares rose 4.00% to $129.11 on a strong trading day, outperforming competitors like Johnson & Johnson (JNJ) and Abbott Laboratories (ABT). The stock reached a new 52-week high, surpassing its previous peak of $128.70. The S&P 500 Index and Dow Jones Industrial Average also saw gains of 1.16% and 1.21%, respectively, with Gilead's trading volume exceeding its 50-day average.

Dow Jones·
DE
GIS
0.00%
US
JNJ
-0.09%
US
ABT
-0.34%
Dow Jones·
DE
GIS
0.00%
US
JNJ
-0.09%
US
ABT
-0.34%
Posts
View More

$Gilead Sciences(GILD.US) breaking out today. None here

Source: Sunrise Trader

© 2026 Longbridge｜Disclaimer